Screener
Aquestive Therapeutics, Inc. AQST Current Debt
Current Debt at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DebtCurrent.
The source filing: Aquestive Therapeutics, Inc.’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 4:10 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001398733-26-000042
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Deferred revenue, current | 1,092 | 1,092 |
| Liability related to the sale of future revenue, current | 1,000 | 1,000 |
| Royalty obligations, current | 51 | — |
| Debt, current | 32 | 9,994 |
| Total current liabilities | 16,478 | 47,608 |
| Debt, long-term, net | 50,654 | 27,519 |
| Royalty obligations, net | 27,835 | 25,941 |
| Liability related to the sale of future revenue, net | 61,168 | 62,023 |
Item 1. FINANCIAL STATEMENTS (Unaudited)
FAQ
- What is Aquestive Therapeutics, Inc.'s current debt?
- Aquestive Therapeutics, Inc. (AQST) reported current debt of $32K in Q2 2026.
- How has Aquestive Therapeutics, Inc.'s current debt changed year-over-year?
- Aquestive Therapeutics, Inc.'s current debt decreased by 99.7% year-over-year, from $9.54M to $32K.
- What does current debt mean?
- The portion of long-term debt maturing within the next 12 months, requiring refinancing or repayment from operating cash flows.
Ask your AI about Aquestive Therapeutics, Inc.'s current debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude